MDS Foundation

The MDS Foundation is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases. Every MDS patient will benefit from our initiatives and research as early as possible.
MDS Foundation ...
read more ↘

 

MDS Foundation
T

Prevalence and Prognostic Information of Lymphopenia in PSS-R Very-Low and Low-Risk MDS: An Analysis From the EU-MDS Registry

By MDS Foundation FEATURING Tobias Silzle
By MDS Foundation FEATURING Tobias Silzle
2 views
April 20, 2022
0 Comments
Login to view comments. Click here to Login
MDS 2021 Congress
22:10
MDS Foundation

Present and Future Management of LR-MDS

Feat. U. Platzbecker
16:01
MDS Foundation

MDS Updates: Targeting TGF-β and IRAK Pathways

Feat. A. Verma
10:18
MDS Foundation

Is Race Important in Genomic Classification of Hematological Neoplas…

Feat. J. Wu
23:35
MDS Foundation

Strategies to Reduce Relapse and Improve Survival Following alloSCT …

Feat. C. Cutler
16:58
MDS Foundation

Mechanisms and Predictors of Drug Resistance in HR-MDS: Intolerance …

Feat. M. Sekeres
18:36
MDS Foundation

Difficult MDS Case: 75 y/o With Stable Disease on DNMTi After 6 Cycl…

Feat. M. Savona
14:32
MDS Foundation

MDS Case: 72 y/o ECOG 0-1, 17% Blasts - Induce & Transplant, HMA…

Feat. A. Giagounidis
15:56
MDS Foundation

Lower-Risk MDS Patient With Higher-Risk Disease

Feat. M. Mittelman
18:06
MDS Foundation

Thrombocytopenia in LR-MDS

Feat. V. Santini
10:32
MDS Foundation

Burden and Management of Acute Myocardial Infarction in MDS

Feat. A. Leslie
24:54
MDS Foundation

How Machine Learning Can Contribute to Prognostic and Predictive Mod…

Feat. A. Nazha
112:33
MDS Foundation

MDS Foundation on Morphology & Flow Cytometry

Feat. A. Porwit, A. Tierens
72:22
MDS Foundation

MDS Foundation on Geriatric Hematologic Malignancies

Feat. S. Alibhai, H. Klepin
55:31
MDS Foundation

MDS Foundation Updates: Genomics 101

Feat. M. Rauh
57:53
MDS Foundation

Genomics for Clinical Diagnostics of Myeloid Neoplasms

Feat. A. Karsan
46:03
MDS Foundation

MDS, AA, PNH, TLGL, PRCA: How to Delineate and Treat

Feat. A. Kulasekararaj
39:34
MDS Foundation

Making Heads and Tails of NGS Printouts and Their Role in MDS

Feat. B. Ebert
30:39
MDS Foundation

Lenalidomide Treatment in MDS

Feat. V. Santini
35:36
MDS Foundation

Optimizing Transfusion Support for Patients With MDS

Feat. Y. Lin
59:52
MDS Foundation

Panel Review of the Greatest Presentations From the MDS Congress 2021

Feat. R. Buckstein, A. Schuh, K. Yee
11:21
MDS Foundation

The Clinical Outcomes and Molecular Profile of OM-CMML Support Its C…

Feat. D. Roman
21:34
MDS Foundation

The Cutting Edge of the Spliceosome

Feat. M. Walter
17:53
MDS Foundation

BET Inhibitors Sensitize CMML to PIM Inhibition Via Downregulation o…

Feat. E. Padron
11:56
MDS Foundation

Prevalence and Prognostic Information of Lymphopenia in PSS-R Very-L…

Feat. T. Silzle
24:49
MDS Foundation

The Evolving Use of Immune Checkpoint Blockade in Management of MDS

Feat. A. Zeidan
24:29
MDS Foundation

Immunotherapy Strategies in MDS

Feat. S. Gill
23:56
MDS Foundation

Role of Innate Immune Signaling in MDS

Feat. D. Starczynowski
25:29
MDS Foundation

Bone Marrow Niche Contributions to MDS Pathogenesis

Feat. H. Medyouf
19:55
MDS Foundation

Inflammatory Signaling in the Pathogenesis of MDS

Feat. D. Sallman